Skip to content
Peptidepedia

How to Use SS-31 (Elamipretide): Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

Subcutaneous Injection (Most Common): The standard route for both clinical and community use. Lyophilized powder is reconstituted with bacteriostatic water to a concentration of 1 mg/mL and administered using an insulin syringe into the abdominal area with rotating injection sites. Subcutaneous injection provides reliable absorption with minimal procedural complexity.

Intravenous Infusion (Clinical Setting Only): Used in cardiac trials such as EMBRACE-STEMI, IV administration requires clinical supervision and is not appropriate for self-administration. The pharmacokinetic profile differs from subcutaneous dosing and is not directly translatable to community protocols.

Oral Administration: Oral bioavailability is significantly reduced compared to injection due to peptide degradation in the gastrointestinal tract. Oral formulations have been explored but subcutaneous injection remains the preferred route for meaningful systemic exposure.

Reconstitution: Add bacteriostatic water slowly along the interior vial wall. Do not inject directly onto the powder under pressure. Gently swirl to dissolve; do not shake vigorously. Allow several minutes for complete dissolution.

Reconstitution, Storage & Prep

SS-31 is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before subcutaneous injection.

Reconstitution Process:

  1. Allow vial to reach room temperature before opening
  2. Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle
  3. Draw the appropriate volume of bacteriostatic water into an insulin syringe
  4. Insert the needle into the vial and inject the water slowly along the interior vial wall. Do not jet the water directly onto the powder
  5. Do not shake. Gently swirl until the powder is fully dissolved (typically several minutes)
  6. Inspect the solution; it should be clear and colorless

Common Reconstitution Ratio:

  • 40 mg SS-31 + 40 mL bacteriostatic water = 1 mg/mL (20 mg per 20 mL)

Storage Guidelines:

  • Lyophilized (unreconstituted): Store at -20°C for long-term; stable at 2–8°C for several months
  • Protect from light and moisture at all times
  • Reconstituted solution: Store at 2–8°C (refrigerator); use within 28 days
  • Discard if solution becomes cloudy, discolored, or contains particulate matter
  • Single-use vials reconstituted with non-preserved sterile water should not be stored

Frequently Asked Questions

They are the same compound. SS-31 is the original research designation used in preclinical and early clinical studies. Elamipretide is the International Nonproprietary Name (generic pharmaceutical name) assigned as the compound advanced through clinical development. Bendavia and MTP-131 are additional names used across different clinical trial programs.

Oral bioavailability is significantly reduced compared to subcutaneous injection. While oral formulations have been explored, subcutaneous administration remains the preferred route for consistent absorption. Injectable forms are standard in both clinical trials and community use.

Cycling necessity is not scientifically established. Clinical trials used continuous dosing for up to 36 weeks without apparent tolerance development. Some users implement 8-weeks-on, 4-weeks-off protocols precautionally, but this practice is not supported by clinical evidence.

Clinical trials lasting up to 36 weeks have not revealed significant safety concerns. No serious adverse events have been definitively attributed to SS-31 in published trials. However, long-term safety data in healthy populations remains limited, and individuals sourcing SS-31 from unregulated research chemical suppliers face contamination risks.

Clinical research has focused on heart failure with reduced ejection fraction, ST-elevation myocardial infarction (ischemia-reperfusion injury), Barth syndrome, and primary mitochondrial myopathy. Preclinical evidence suggests potential applications in renal ischemia-reperfusion injury, skeletal muscle atrophy, neurodegenerative processes, and age-related mitochondrial decline.

Lyophilized (powder) form should be stored at -20°C for long-term storage, or at 2–8°C for shorter-term storage of several months. Protect from light and moisture. Once reconstituted with bacteriostatic water, store at 2–8°C (refrigerator) and use within 28 days. Discard if the solution becomes cloudy or discolored.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
  2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  3. Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004230.
  4. Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
  5. Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17-28.
  6. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
  7. Stealth BioTherapeutics. Elamipretide Development Program.
  8. Sabbah HN, et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206.
  9. Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
←Read the full SS-31 (Elamipretide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”